TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • May 15th, 2023 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations
This TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made as of January 4, 2023 (the “Effective Date”) by and between Baylor Biosciences, Inc., a company organized and existing under the laws of the People’s Republic of China (“Baylor”), Bellerophon Pulse Technologies LLC, a limited liability company organized and existing under the laws of Delaware, the United States (“Bellerophon”), and Bellerophon Therapeutics, Inc., a company organized and existing under the laws of Delaware, the United States (“BTI”). Bellerophon and Baylor shall hereinafter be referred to collectively as the “Parties” and individually as a “Party” (and for the purposes of Sections 17.3 through 17.12, inclusive, a “Party” or “Parties” shall be read as including BTI).
